IGI Laboratories Signs Product Development Agreement With CHS
US-based IGI Laboratories has signed a product development agreement with Cancer Health Solutions Resources.
IGI with Cancer Health Solutions Resources (CHS) will develop a Novasome technology based over the counter sunscreen product containing CHS’s proprietary ingredients that may enhance the antioxidant effect of normal skin cells.
Rajiv Mathur, president and CEO of IGI, said: “We look forward to working with CHS on this project to develop a sunscreen that may have an antioxidant effect on normal cells and may protect the cells from the sun’s UV rays.
“Additionally, our Novasome technology offers the added benefit of a unique capability of combining incompatible drug molecules into one product.”